Introduction: The forced degradation determine the intrinsic stability of the molecule by
INTRODUCTION
Forced degradation is a degradation of new drug substance or drug product at more severe conditions than accelerated conditions. Forced degradation studies afford the information about identification of possible degradants; degradation pathways and inherent stability of the active pharmaceutical ingredient. It also offers the information about any possible polymorphic or enantiomeric substances and difference between drug related degradation and excipient interferences. New Drug Application (NDA) registration requires data of forced degradation studies in the form of forced degradation products, degradation reaction kinetics, structure, mass balance, drug peak purity, etc. Therefore, forced degradation and impurity profiling is one of the input for NDA registration manuscript [1] . Due to the presence of impurities or degradation products USFDA has recalled the finished pharmaceutical products; few of them are as: adagen (pegademase bovine) injection, azelastin hydrochloride ophthalmic solution, brimonidine tartrate ophthalmic solution, cyclopirox gel, diflorasone diacetate cream, fludeoxyglucose F18 injections, hydroxyzine hydrochloride oral solution, leflunomide tablets, pediatric atropine sulfate injection, prednisolone sodium phosphate oral solution, ropinirole hydrochloride tablets and topiramate tablets [2] . Intrinsic stability of armodafinil hydrochloride was explored by forced degradation and impurity profiling, where structure of four degradation products were established and possible pathway was postulated. In the present work, whole research methodology was adopted from the Jain et al [3] .
Chemically, olopatadine (OLO) is 11-((Z)-3-(dimethyl-amino) propylidene)-6,11-dihydrodibenz[b,e] oxepin-2-acetic acid [4] and indicated for allergic rhinitis, urticaria, itching resulting from skin diseases such as eczema/dermatitis, prurigo, pruritus cutaneous, psoriasis vulgaris, multiform exudative erythema. OLO primarily acts as a selective histamine H1 receptor antagonist. It also inhibits production and release of chemical mediators such as leukotriene and thromboxane; the release of the neurotransmitter tachykinin [5] [6] [7] [8] [9] . Although, analytical methods for OLO determination in different matrix have been reported viz. radioimmunoassay [10] , LC with tandem mass spectrometry [11] , LC-ESI-MS-MS [12] [13] , capillary zone electrophoretic method [14] , HPLC and HPTLC [15] ; but there is on study is reported on forced degradation profiling including intrinsic stability of OLO. The objective of forced degradation is to provide guidance for developing of executing purposeful degradation experiments for pharmaceutical u n c o r r e c t e d p r o o f 4 | P a g e drug candidates. The ICH Guideline provides some guidance on stress testing or purposeful degradation stress testing helps to determine the intrinsic stability of the molecule by establishing degradation pathways in order to identify the likely degradation products [16] . The objective of present research work was to establish intrinsic stability and forced degradation profiling of OLO by reverse phase high performance liquid chromatography diode array detector high-resolution mass spectrometry (RP-HPLC-DAD-HRMS) technique.
EXPERIMENTAL

Chemicals and reagent
Working standard of olopatadine hydrochloride (OLO) was gifted by Ranbaxy Laboratories Limited, Gurgaon, Harayana. HPLC grade solvents (methanol and acetonitrile), formic acid, hydrochloric acid, sodium hydroxide and hydrogen peroxide were procured from Merck Specialties Private Limited Mumbai, India. Triple distilled water was prepared in-house.
Instrument and chromatography
All dilutions, mobile phase and other solutions were filter through 0. 
Standard solution
Accurately weighed amount of 100 mg of OLO was dissolved in 100 mL of methanol to prepare stock P (1000 g/mL). Aliquot of the stock P was diluted to prepare stock Q (100 g/mL), which was used to prepare series of standard dilutions viz. 2, 4, 6, 8 and 10 g/mL of OLO.
Method Validation
As per ICH guidelines [17] [18] [19] , the proposed method was validated for the stability indicating assay and to establish inherent stability of OLO drug with forced degradation profiling in different conditions by RP-HPLC determination. The developed method was validated to assure the reliability of results of analysis for different parameters viz. linearity, range, accuracy, precision, robustness, limit of quantification (LOQ), limit of detection (LOD) and specificity.
The serial dilutions (2-10 g/ml) of the OLO in 50% methanol in triplicates were used for the linearity determination. Accuracy was determined by recovery method by spiking the standard solution to the pre-analyzed samples. Precision of the method was studied under the head of repeatability and intermediate precision. The six replicates of 10 g/ml were chromatographed subsequently to assure the repeatability. The intermediate precision was determined by day to day analysis variation and analyst to analyst variation in the linearity range. The robustness of the method was studied with the variation in the temperature (20, 25 and 30°C) and content of formic acid (0.1%) in aqueous phase variation by 5% change. Limit of detection (LOD) and limit of quantification (LOQ) were determined by signal-to-noise ratio. The specificity was ascertained by degrading the drug sample in stressed conditions. Sample solution stability was demonstrated by analyzing six replicates of 10 g/mL OLO standard samples at different time intervals with freshly prepared mobile phase on each time.
Forced degradation
Forced degradation studies of bulk drug included appropriate solid state (thermal and photolytic) and solution state stress conditions (hydrolytic and oxidative). The stock solution was used for the forced degradation study to provide an indication of the stability indicating property and u n c o r r e c t e d p r o o f 6 | P a g e specificity of proposed method. Accurately weighed about 100 mg OLO was dissolved in 50 mL of methanol and volume was made upto 100 mL with water/ 0.2 N HCl / 0.2 N NaOH to perform hydrolytic degradation in neutral (water), acidic (0.1 N HCl) and alkali (0.1 N NaOH) conditions, respectively and refluxed at 60°C. Bulk drug (powder form) was exposed to 60 °C (hot air oven) and UV light separately for temperature and ultra-violet degradation, respectively.
Oxidative degradation of OLO was performed in 3% and 10% H2O2 solution. Prior to injection, samples were withdrawn at appropriate time, neutralized (in case of acid and alkali hydrolysis) and the solutions were diluted with 50% methanol. Thermal and photolytic degraded drug (solid powder) was dissolved in 50% methanol to prepare sample for injection.
RESULT AND DISCUSSION
Optimization of chromatographic conditions
Although, OLO was eluted at 3.77 minute by the mixture of 0.1% formic acid and methanol (35:65) on Zorbax Eclipse Plus C18 column (250 mm × 4.6 mm, 5 μm) at 1.0 mL/min flow rate and it was successfully applied for determination of the OLO drug in dosage form [20] but it was not suitable for the separation of the degradation products along with OLO.
Thus, chromatographic conditions were optimized to develop a stability-indicating assay method to separate the related compounds and degradation products from the drug content. RP-HPLC mode chromatography was selected based on the solubility and pKa value of OLO. ZORBAX Eclipse Plus C18 column (250 × 4.6 mm, 5 m) was used separate all degradants along with drug. The wavelength of 300 nm was selected due to maximum absorbance of all the degradation product and drug, which was optimized by 1260 DAD VL, 20 Hz detector.
Broadening and splitting of peak were observed with the both mobile phases methanol and water (50:50) and acetonitrile and water (50:50). Drug's peak was merged with diluent as organic phase was increased. After using acidic aqueous phase (pKa of drug 4.29); the broadening and tailing of OLO peak was persisted. It was improved by increasing organic phase (methanol) upto 65%. Further, methanol content was reduced to 60% to resolve grouped 4-5 peaks in degraded samples; where little separation was found but peak shapes were not acceptable. Then, acetonitrile content was incorporated in organic phase along with methanol (50:50). All peaks of degraded samples were found very sharp but not well resolved with 0.1% formic acid and above u n c o r r e c t e d p r o o f organic phase (40:60). Degradant peaks were well separated till 6 min when this ratio was reversed (60:40); but highly tailing was observed in drug's peak. Thus, degradants were well resolved in 60:40 ratios while drug eluted in 40:60; then it was concluded to run gradient mode.
Degradation products were resolved before drug peak but few of them were merged with dug peak in between 11-13 min and two degradation products were merged to each other at 16 Most of degradation products were resolved but tailing in drug peak was seen which may be due to less exposure to the organic phase, so it was decided to increase organic content in mobile 
Method validation
The consistence performance of HPLC system was assured by system suitability parameters. As per section 4.5.4.1, six replicates of OLO samples were injected, and column performances like tailing factors, retention time and number of theoretical plates were observed. The values of % relative standard deviation (% RSD) for these parameters were found within the acceptance criteria of system performance. OLO has better separation in set of conditions as the higher theoretical plates (59526) with less than one unit of % RSD (0.88). The tailing factor was found to be 0.68 with acceptable % RSD. The capacity factor was 15.02 i.e., OLO has sufficient opportunity to interact with the stationary phase resulting in differential migrations. The coelution of impurities or degradants is generally investigated by examining the peak purity using a PDA detector. Three-dimensional view of the chromatogram has been confirmed that there was no peak around the OLO elution time. Here, the peak purity at 11.62 min was 1.0; there was no respectively. Limit of detection (LOD) and limit of quantification (LOQ) were determined by signal-to-noise ratio. These were found to be 0.045 μg/mL and 0.149 μg/mL, which show the sensitivity of the developed method. The % RSD value was less than two. Analysis of degraded drug sample in stressed conditions was evidence for specificity of the method. The retention time, peak symmetry, peak purity and UV spectrum of the recorded chromatogram different samples were confirmed to assure the specificity. The AUC of OLO peak in chromatogram has been decreased with increase in the AUC of degradant's peak. This experimental evidence confirmed that the developed method was specific for the analysis of OLO. The stability of OLO was assured during analysis by response ratio. The response ratio of the drug at all concentration level was varied in between 16565.67-16973.33 with % RSD of 0.89. It is evidence that the drug is stable in selected solution at room temperature and RP-HPLC method is continuously sensitive toward the analyte.
u n c o r r e c t e d p r o o f
Forced degradation profiling
Acidic degradation: Five degradation products (DPs) viz. OLO1 (5.17), OLO2 (7.87), OLO3 (11.11), OLO4 (12.65) and OLO5 (12.91) were observed in acidic condition (Fig 1) . OLO5 was major DP which was increased with time and peak area of OLO was decreased. All DPs were appeared on first day except OLO1 and OLO2 which were appeared on fourth and second day, respectively. Peak area of OLO3 and OLO4 was increased first and then decreased. Other two DPs OLO1 and OLO2 increased with time.
Alkaline degradation: OLO was gradually degraded into four DPs viz. OLO3 (11.11), OLO6 (12.07), OLO5 (12.91) and OLO7 (17.48) in alkaline condition (Fig 2) . OLO3 and OLO5 were common DPs in acidic and alkaline conditions while OLO6 and OLO7 were newer DPs in basic degradation. OLO5 and OLO6 were two major DPs; OLO5 was increased with time while OLO6 has zig-zag pattern of peak area with time. Concentration of both OLO3 and OLO7 were increased with time.
Neutral degradation: All DPs of neutral condition were also found in acidic condition while OLO3 and OLO5 were common in all three type of hydrolytic degradation (Fig 3) . OLO5 was major DP in all conditions. OLO was gradually degraded and peak area of all DPs increased with time in neutral conditions. RP-HPLC analysis of stressed samples of OLO in thermal, oxidative and photolytic degradation has shown that there was no degradation in these conditions. It might be possible that due to solid sample in thermal stress condition no degradation was observed.
Thus, in acidic condition, five degradation products (DPs) viz. OLO1, OLO2, OLO3, OLO4 and OLO5 were observed. OLO5 was major DP which was increased with time and peak area of OLO was decreased. In addition to OLO3 and OLO5; two more DPs were observed in alkaline condition viz. OLO6, and OLO7 in alkaline condition. OLO5 and OLO6 were two major DPs; OLO5 was increased with time while OLO6 has zig-zag pattern of peak area with time. All DPs of neutral condition were also found in acidic condition while OLO3 and OLO5 were common in all three type of hydrolytic degradation. Thus, OLO has similar pattern of degradation profiling in all hydrolytic conditions (acidic, alkaline and neutral) (Fig 4) . No degradation was found in thermal and UV light exposure, as these were performed on solid powder of OLO, so it might be u n c o r r e c t e d p r o o f possible that degradation is less prone in the solid powder. Similarly, oxidative degradation was also not observed for ten days.
Degradation pathway and impurity profiling
Standard drug OLO: LC-MS study was performed in positive mode using leucine enkephalin as standard, where OLO and its impurity (OLO-Imp) were observed at RRT of 1.00 and 1.11, respectively. The ESI mass spectrum of OLO showed protonated molecular ion [ Fig. 5 ).
An impurity OLO-Imp (OLO5) was observed in ESI spectrum, and its protonated molecular ion [M+H] + was observed at m/z 352.1840 along with its isotopic abundance (Fig. 6 ). It's structure was analogue of OLO and proposed as 11 -[(3 -dimethylamino)-propylidene] -6, 11-dihydrodibenz[b,e]oxepin-2-propanoic acid (Fig. 6) . It was also used as internal standard for metabolite study [10] . (Fig 7) . The ppm error in mass was less than five units (Table 2 ).
Alkaline degradation: MS spectrum of alkaline sample of OLO was observed as similar to MS spectrum of acidic conditions. The degradation pathway and fragmentation pattern of OLO and its degradation products were as similar to acidic conditions (Fig. 8) . Only ppm error in mass varies from acidic condition (Table 3) . (Fig. 9) . The proposed structure was further advocated by its degradation pattern (207.1623 → 177.1154 → 157.0891) ( Table 4 ). OLO3, OLO and OLO5 were also characterized in neutral condition as similar to above both acidic and alkaline conditions. The ppm error in mass is different from above conditions but most of the error is below 5 units (Table 4) .
Thus, OLO and its impurity (OLO-Imp) were observed at RRT of 1.00 and 1.11, respectively in LC-MS study. OLO-Imp was recognized as analogue structure of OLO and proposed as 11 -[(3-dimethylamino)-propylidene] -6, 11-dihydro-dibenz[b,e]oxepin-2-propanoic acid (Fig 10) . In addition to OLO, sodium salt of OLO (OLO3) and OLO5 (OLO-Imp) were observed in both MS spectrum of acidic and alkaline conditions sample at RRT of 0.96 and 1.11. OLO3 was observed in all three degradation conditions and identified as sodium salt of OLO (OLO is carboxylic acid derivative). Additionally, OLO1 (RRT = 0.44) was identified as (2-(4-(dimethylamino)butyl) phenyl)methanol which may be formed by cleavage of tricyclic ring in neutral condition. OLO is acetic acid derivative along with oxepin ring and tertiary nitrogen, which is quite stable form of drug. There is no vulnerable functional group which liable to convert or breakdown into degradation products under stressed or forced degradation conditions. So, OLO forms relatively slow and less number of degradation products.
CONCLUSION
OLO has similar pattern of degradation profiling in all hydrolytic conditions (acidic, alkaline and neutral), while no degradation was found in thermal, UV light and oxidative conditions for ten days. OLO-Imp was recognized as analogue structure of OLO and proposed as 11 -[(3- 
